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Background: Most non-small cell lung cancers occur in elderly and frequently comorbid
patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy
regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve
tumor control paralleled by modest toxicity profiles.
Patients andMethods: The ModuLung trial is a national, multicentre, prospective, open-
label, randomized phase II trial in patients with histologically confirmed stage IIIB/IV
squamous (n  11) and non-squamous non-small cell (n  26) lung cancer who failed
first-line platinum-based chemotherapy. Patients were randomly assigned on a 1:1 ratio to
the biomodulatory or control group, treated with nivolumab. Patients randomized to the
biomodulatory group received an all-oral therapy consisting of treosulfan 250 mg twice
daily, pioglitazone 45mg once daily, clarithromycin 250 mg twice daily, until disease
progression or unacceptable toxicity.
Results: The study had to be closed pre-maturely due to approval of immune checkpoint
inhibitors (ICi) in first-line treatment. Thirty-seven patients, available for analysis, were
treated in second to forth-line. Progression-free survival (PFS) was significantly inferior for
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biomodulation (N  20) vs. nivolumab (N  17) with a median PFS (95% confidence interval)
of 1.4 (1.2–2.0) months vs. 1.6 (1.4–6.2), respectively; with a hazard ratio (95% confidence
interval) of 1.908 [0.962; 3.788]; p  0.0483. Objective response rate was 11.8% with
nivolumab vs. 5% with biomodulation, median follow-up 8.25 months. The frequency of
grade 3–5 treatment related adverse events was 29% with nivolumab and 10% with
biomodulation. Overall survival (OS), the secondary endpoint, was comparable in both
treatment arms; biomodulation with a median OS (95% confidence interval) of 9.4
(6.0–33.0) months vs. nivolumab 6.9 (4.6–24.0), respectively; hazard ratio (95%
confidence interval) of 0.733 [0.334; 1.610]; p  0.4368. Seventy-five percent of
patients in the biomodulation arm received rescue therapy with checkpoint inhibitors.
Conclusions: This trial shows that the biomodulatory therapy was inferior to nivolumab on
PFS. However, the fact that OS was similar between groups gives rise to the hypothesis
that the well-tolerable biomodulatory therapy may prime tumor tissues for efficacious
checkpoint inhibitor therapy, even in very advanced treatment lines where poor response
to ICi might be expected with increasing line of therapy.
Keywords: biomodulation, anakoinosis, NSCLC, checkpoint inhibition, pioglitazone, nivolumab, priming,
metronomic chemotherapy, clarithromycin
INTRODUCTION
Despite improvements in the first-line treatment of patients with
advanced non-small cell lung cancer (NSCLC), nearly all patients
experience disease progression. Management of patients with
advanced NSCLC is individualized based upon molecular and
histologic features of the tumor (Planchard et al., 2018). Until
recently, patients with previously untreated NSCLC with no
driver mutation were treated with mainly platinum-based first-
line chemotherapy. Second-line treatment consisted of a different
line of chemotherapy with single-agent docetaxel as the main
option. The advent of inhibitors of the programmed cell death
protein 1 (PD-1) or its ligand (PD-L1) in NSCLC has improved
patients’ outcomes and changed the therapeutic landscape. Anti-
PD-1 were first shown to be superior to docetaxel as second-line
treatment (Borghaei et al., 2015; Herbst et al., 2016; Horn et al.,
2017; Rittmeyer et al., 2017; Planchard et al., 2018). This was
followed by results of first-line anti-PD-1 combined with
chemotherapy showing superiority to chemotherapy alone in
the first-line treatment of these patients (Rittmeyer et al.,
2017; Gandhi et al., 2018; Socinski et al., 2018). Just when the
ModuLung trial was initiated, nivolumab became a standard
second-line option in both squamous and non-squamous
NSCLC in Germany. However, anti-PD-1 in first line was not
yet standard treatment.
Our group has shown that a combination of therapies
modulating tumor angiogenesis, inflammation and immune
response can result in a significant survival benefit in patients
with various advanced malignancies (reviewed in (Hart et al.,
2015)). This approach, called biomodulation, aims to induce
communicative reprogramming of dysregulated cellular and
intercellular homeostasis (anakoinosis) (Heudobler et al., 2019b).
In the trial reported here, biomodulation consisted of a combination
of pioglitazone, clarithromycin and low-dose metronomic
treosulfan. Pioglitazone - a drug approved for type 2 diabetes—is
a potent peroxisome proliferator-activated receptor (PPAR)-alpha/
gamma agonist. PPAR-gamma activation has been proposed as a
therapeutic strategy for NSCLC (Reichle, 2010; Giaginis et al., 2012;
Khandekar et al., 2018; Ciaramella et al., 2019). Clarithromycin—a
macrolide antibiotic—has strong anti-inflammatory and
immunomodulatory properties, especially in the lung (Kanoh and
Rubin, 2010; vanNuffel et al., 2015). A study reported that long-term
treatment with clarithromycin increased the median survival of
patients with non-small cell lung cancer (Mikasa et al., 1997). In
cachectic NSCLC patients, clarithromycin reduced the progression
of cancer-associated cachexia (Sakamoto et al., 2001).
Treosulfan—an alkylating agent widely used in Germany—was
used in a metronomic fashion to target the tumor
microenvironment (André et al., 2014).
With limited data on biomodulation in NSCLC the ModuLung
trial explores the efficacy and safety of a biomodulatory regimen
compared to a standard of care (SOC) regimen; i.e., nivolumab. With
previous trials inmultiple entitites showing favorable safety profiles for
biomodulation (Thomas et al., 2015; Vogelhuber et al., 2015; Ugocsai
et al., 2016; Walter et al., 2017; Heudobler et al., 2019a) the trial also
addresses the medical need for low-toxic therapies in relapsed or
refractory non-small cell lung cancer (NSCLC). Moreover, with the
emergence of immune checkpoint inhibitors in the NSCLC therapy
landscape the study generates new hypotheses on therapy seqences
and combinations as well as possible synergistic effects of immune
checkpoint inhibitors and biomodulatory regimens.
PATIENTS AND METHODS
Patients
Eligible patients were patients with histologically or cytologically
confirmed locally advanced, unresectable or metastatic NSCLC
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who had experienced disease progression during or following
treatment with a platinum-containing regimen. Patient with stage
IIIB eligible for definitive chemoradiotherapy were excluded.
Patients had to have an Eastern Cooperative Oncology Group
performance status of 0 or 1. Patients with epidermal growth
factor receptor mutation or anaplastic lymphoma kinase
rearrangement were eligible if they had progressed during or
after first-line targeted therapy, since further standard targeted
therapy was lacking for this patient population. Patients with
known active or untreated central nervous system metastases
were excluded.
The institutional review boards and ethic committees of all
participating centers approved the protocol (ethics committee of
the University of Regensburg approval No.: 15-112-0124). The
study was conducted in accordance with the Declaration of
Helsinki and applicable national and European laws. All
patients provided written informed consent.
Study Design
The ModuLung trial (EUDRACT 2014-004095-31,
NCT02852083) is a national, multicentre, prospective, open-
label, randomized phase II trial in advanced NSCLC who
failed first-line platinum-based chemotherapy. Patients were
randomly assigned on a 1:1 ratio to the experimental or to the
control group. Patients randomized to the experimental group
received an all-oral therapy consisting of treosulfan 250 mg twice
daily, pioglitazone 45 mg once daily, clarithromycin 250 mg twice
daily, until disease progression or unacceptable toxicity. Dosage
of each drug was choosen based on previous biomodulatory trials
(Reichle A, 2010; van Nuffel et al., 2015; Vogelhuber et al., 2015;
Heudobler et al., 2019a).Patients randomized to the control group
received 3 mg per kilogram of nivolumab every 2 weeks until
disease progression or unacceptable toxicity. No crossover was
allowed between the both arms. Initially, patients randomized to
the control group were to receive a docetaxel 75 mg/m2
intravenously on day 1 plus twice daily nintedanib 200 mg p.o.
on day 2–21 (non-squamous cell histology only) of each 21-days
cycle until disease progression or unacceptable toxicity, for a
maximum of 6 cycles. Three patients in the control group
received one or two cycles of docetaxel and nintedanib which
was discontinued due to progressive disease. However, the trial
protocol was rapidly amended to reflect changes in the standard
treatment in the control group and all patients in the control
group then received the new standard treatment (nivolumab).
Additional supportive treatment was performed according to
standard practices at the participating centres. Follow-up was
performed every 3 months by the local oncologist.
Randomisation, Endpoints and Statistical
Analysis
Randomisation of eligible patients was done centrally by a Contract
Research Organisation (ClinAssess) and was stratified according to
squamous cell or adenocarcinoma histology. The primary endpoint
of the studywas progression-free survival (PFS) defined as time from
randomisation to progression or death from any cause, whichever
occured first. Progression was defined as progressive disease
according to RECIST criteria 1.1 (Eisenhauer et al., 2009).
Clinical secondary endpoints were overall survival (OS), duration
of response, safety, health-related quality of life using the European
Organisation for Research and Treatment of Cancer (EORTC)
Quality-of-Life Questionnaire Core 30 (QLQ-C30) and its Lung
Cancer Module (LC13).
The study was designed to detect a change of median PFS from
3–4.5 months. Using a phase II screening design as proposed by
Rubinstein and colleagues (Rubinstein et al., 2005), a power of 0.8
and an alpha of 0.20, 69 events (progression or death) were needed to
show superiority of the experimental arm. To observe 69 events, 80
evaluable patients were required (40 per group). To account for an
estimated drop-out rate of 5%, 86 patients were to be randomized.
The intention-to-treat population (Full analysis set) was used for all
efficacy analyses. Patients’ demographics and baseline characteristics
were summarized using descriptive statistics (mean, standard
deviation, median, minimum, and maximum values) for
continuous parameters and frequencies and percentages for
categorical data. PFS and OS were estimated using the Kaplan-
Meier method and compared between groups by the Log-Rank
test. Hazard Ratio (HR) comparing the two groups and their 95%
Confidence Intervals (CIs) were estimated from a Cox proportional
hazards model. Safety analyses included incidence of serious adverse
events. All statistical tests were 2-sided with a 5% Type I error except
for the primary endpoint for which a 20% type I error was used as per
trial design. The study was powered to assess superiority of the
experimental arm over the standard arm concerning PFS assuming
that the standard will result in a median PFS of 3 months and that the
experimental will prolong median PFS to 4.5 months.
All data were collected and analyzed using the statistical
analysis software SAS®.
EORTC QLQ-C30
Analysis of EORTC QLQ-C30 and the lung cancer module QLQ-
C30-L13 were done according to statistical analysis plan. Nine of
fifteen scales for quality of life were selected for analysis.
Wilcoxon-tests were performed for comparison of the
treatment arms at baseline, cycle 2, cycle 3 and final examination.
RESULTS
Between April 2016 and June 2018, 40 patients from seven sites in
Germany were randomly assigned to the biomodulatory treatment
(n  20) or to nivolumab (n  20). Figure 1 depicts the CONSORT
diagram. The sponsor terminated the trial early because of the
approval of anti-PD-1 in the first-line treatment of NSCLC. The
control arm of the ModuLung trial thus became inappropriate. As
there is no consensus on a standard control arm treatment following
these changes, no amendment could prevent the termination of the
trial. Data extract was done March 12, 2020.
Patients’ Characteristics
Patients’ characteristics are summarized in Table 1. The
CONSORT diagram (Figure 1) illustrates the repartition of
the patients within the two study cohorts. Three patients were
excluded due to withdrawal of consent, protocol violation and
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serious adverse events before receiving treatment. Therefore, the
safety set comprises altogether 37 patients.
Patients’ characteristics were well balanced between the
biomodulatory arm and the nivolumab arm, except for the
number of patients with controlled cerebral metastases (3 vs.
0, respectively) and the mean time since metastatic disease (10.1
vs. 13.3 months, respectively). Within each study group similar
proportions of patients were treated in second- to forth-line.
Seventeen patients (85%) in the biomodulatory arm received
further anti-neoplastic therapy, 15 patients therefore (75%)
received anti-PD-(L)1 (nivolumab or atezolizumab) following
progression. 10 patients (59%) in the nivolumab arm were
treated with further anti-neoplastic therapy following
progression (Table 1).
Efficacy
After a median follow-up of 8.25 months, there was a significant
difference in PFS (Figure 2) between the study arms in favor of
nivolumab (HR, 1.908; 95% CI, 0.962 to 3.788; p  0.0483). The
median PFS time was 1.4 (1.2–2.0) months in the biomodulatory
arm and 1.6 (1.4–6.2) months in the control arm B. Best response
was one partial response (5%) and one stable disease (5%) in the
biomodulatory arm, two partial responses (11.8%), and four
stable diseases (23.5%) in the nivolumab arm; with an
objective response rate of 5% vs. 11,8%, p  0.584. There was
no difference in the secondary endpoint median OS (HR 0.733;
95% CI 0.334–1.610; p  0.4368) as shown in Figure 2, with a
median OS of 9.4 (6.0–33.0) months vs. 6.9 (4.6–24.0) months,
respectively.
Safety
After a median follow-up of 8.25 months, the mean treatment
duration was 2.6 months [standard deviation (SD), 3.2 months]
overall, in the biomodulatory arm 2.0 months (SD, 2.4 months),
in the nivolumab arm 3.4 months (SD, 3.8 months),
respectively.
In the pooled safety analysis, treatment-emergent adverse
events (TEAEs) and treatment-emergent serious adverse events
(TESAEs) were reported in fewer patients treated with
biomodulatory therapy than in patients treated with nivolumab
after a median follow-up of 8.25 months. 15 patients (75.0%) in the
biomodulatory arm and 14 patients (82.4%) in the nivolumab arm had
at least one TEAE of any grade. Study medication-related TEAEs of
any grade were observed in nine patients (45%) treated with
biomodulation and in seven patients (41.2%) treated with
nivolumab. Typical treatment-related select TEAEs in the
biomodulation arm were peripheral edema, likely due to
pioglitazone treatment, N  3 (15%). Six nivolumab-treated patients
had first onset of treatment-related typical AEs in GI, hepatic, renal,
nervous system or pulmonary categories. There were two study
medication-related TEAEs by maximum NCI-CTCAE grade 3-5 in
the biomodulatory arm (10%), and five (29%) in the nivolumab arm.
The cumulative TESAEs, NCI-CTCAE grade 3–5, are
presented in Table 2. No patient in the biomodulatory arm
and one patient (5.9%) in nivolumab arm had at least one
TESAE related to study medication. During biomodulation,
NCI-CTCAE grade 3–5 toxicities leading to treatment
discontinuation occurred less frequently in 5 vs. 29%,
respectively. TESAEs in most categories resolved but led to
death in the nivolumab arm in N  3 cases (17.6%).
In the biomodulatory arm, scheduled dose reductions were
performed in 18% of the cycles for treosulfan and pioglitazone,
respectively, and in 16% for clarithromycin while there were no
relevant dose changes for the patients treated with nivolumab.
Responders in the biomodulatory arm had also received dose
reductions. Thus, there seems to be no negative impact of dose
reduction on outcome.
Quality of Life (EORTC QLQ-C30)
Quality of Life (EORTCQLQ-C30) results were available from 15
patients (75.0%) in the biomodulation arm and 12 patients
(70.6%) in the nivolumab arm who filled out the questionnaire
at baseline (before start of study therapy). Nine (45.0%) and 6
(35.5%) patients filled out the questionnaire at end of treatment
visit. For the global health status (QL2) the p-values are 0.3523,
0.6094, 0.5297, and >0.9999. As well, no statistical significant
differences between the treatment arms were detectable for the
other eight scales.
FIGURE 1 | CONSORT flowchart of the ModuLung trial.
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TABLE 1 | Baseline patients’ characteristics (N  37).
Biomodulation, N = 20 Nivolumab, N = 17
Age, years
Mean (SD) 65.4 (±7.4) 61.2 (±7.1)
Range 56–81 50–70
Gender, N (%)
Female 4 20% 4 24%
Male 16 80% 13 76%
Ethnicity
Caucasian 20 100% 16 94.1%
African 0 0% 1 5.9%
ECOG performance status, N (%)
0 12 60% 10 58.8%
1 8 40% 7 41.2%
Duration of disease, in months
Mean (SD) 16.6 (±18.6) 20.5 (±20.1)
Duration of metastatic disease, in months
Mean (SD) 10.1 (±7.6) 13.3 (±13.2)
Histology, N (%)
Squamous cell carcinoma 6 30% 5 29%
Adenocarcinoma 14 70% 12 71%
Grading according to WHO
G2 0 0% 1 5.9%
G3 4 20% 5 29.4%
G3-4 12 60% 8 47.1%
GX 4 20% 3 17.6%
EGFR or ALK alteration, N (%)
EGFR wild type 11 55% 12 70.6%
EGFR 1 5% 0 0%
ALK 0 0% 1 5.9%
Unknown 8 40% 4 23.5%
Stage, N (%)
IIIB 1 5% 0 0%
IVA 5 25% 5 29.4%
IVB 14 70% 12 70.6%
Location of metastatic sites
Brain (controlled) 3 15% 0 0%
Lung, pleura 13 65% 10 58.8%
Liver 3 15% 3 17.6%
Bone 5 25% 6 35.3%
Adrenal gland 2 10% 2 11.8%
Kidney 0 0% 1 5.9%
Other 13 65% 11 64.7%
Number of metastatic sites
1 8 40% 7 41.2%
2 8 40% 5 29.4%
3 2 10% 4 23.5%
4 1 5% 1 5.9%
5 1 5% 0 0%
Previous treatment, N (%)
Platinum-based chemotherapy 20 100% 17 100%
Radiotherapy 9 45% 12 70.6%
Number of lines of chemotherapy, N (%)
1 13 65% 10 59%
2 6 30% 6 35%
3 1 5% 1 6%
Consecutive therapies after progression
Checkpoint inhibitor 15 75% 4 24%
Chemotherapy 9 45% 10 59%
No further tumor-directed therapy 3 15% 7 41%
Comorbities
Chronic obstructive pulmonary disease 7 35% 9 53%
Coronary heart disease 8 40% 5 29%
Arrythmia 3 15% 4 24%
Occlusive peripheral arterial disease 1 5% 2 12%
Thromboemolism 4 20% 0 0%
(Continued on following page)
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DISCUSSION
Our trial, though terminated prematurely, shows that
biomodulatory treatment is inferior to nivolumab on PFS.
There was no difference in OS with the limitation that the
study was not powered to assess non-inferiority/superiority
concerning the secondary endpoint OS. Quality of life was
similar in both arms, but differences in terms of toxicity were
observed. With a proportion of more than one third of patients
enrolled for third- and fourth-line in both study arms, PFS for the
control arm, nivolumab, is expectedly inferior to that in the
CheckMate 017 and CheckMate 057 trials or atezolizumab
treatment (Horn et al., 2017; Rittmeyer et al., 2017). The
result is in line with retrospective data on decreasing efficacy
TABLE 1 | (Continued) Baseline patients’ characteristics (N  37).
Biomodulation, N = 20 Nivolumab, N = 17
Diabetes mellitus 5 25% 4 24%
Hypertension 6 30% 9 53%
Depression 4 20% 2 12%
Neurologic disorder 3 15% 5 29%
Renal insufficiency 2 10% 3 18%
Previous cancer 2 10% 0 0%
Smoker/former smoker 18 90% 17 100%
FIGURE 2 | (A) Kaplan–Meier representation of the progression-free survival according to the treatment group. (B) Kaplan–Meier representation of the overall
survival according to the treatment group.
TABLE 2 | Treatment-emergent serious adverse events (TESAEs) by maximum NCI-CTCAE grade 3–5 (N  37)
System, organ according NCI-CTCAE Biomodulatory
therapy N = 20
Checkpoint
blockade N = 17
N % N %
Cardiac disorders Cardiac failure – – 1 5.9
Pericardial effusion – – 1 5.9
Gastrointestinal disorders Autoimmune colitis – – 1 5.9
Infection, Infestation Peridontitis – – 1 5.9
Pneumonia – – 3 17.6
Injury, poisoning, procedural complications Femur facture 1 5.9
Thoracic vertebra fructure 1 5.0 – –
Nervous system disorders Cerebral hemorrhage – – 1 5.9
Renal and urinary disease Renal failure – – 1 5.9
Hyronephrosis – – 1 5.9
Respiratory, thoracic and mediastinal disorders Pleural effusion 1 5.0 – –
Skin and subcutaneous tissue disorders Skin ulcer 1 5.0 – –
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 5995986
Heudobler et al. ModuLung Trial in r/r NSCLC
of nivolumab with increasing number of preceding lines of
chemotherapy (Rizvi et al., 2015; Lang et al., 2019).
PFS in the biomodulatory treatment arm is significant inferior
to nivolumab treatment. Nevertheless, biomodulation with
pioglitazone, clarithromycin and metronomic treosulfan
emphasizes for the first time that the combination has
immediate concerted activity resulting in objective response
and disease stabilization. Surprisingly preceding biomodulation
might have reached out on outcome of consecutive third- to fifth-
line therapy with nivolumab, as indicated by a median OS rate in
the experimental arm comparing with that of second-line
treatment in CheckMate 017 and CheckMate 057 trial (Horn
et al., 2017).
The clinical discrepancy between poor PFS in the
biomodulation arm and a corresponding median OS equal to
nivolumab second-line therapy may be discussed on the
background of pre-clinical data showing multifold
biomodulatory activities of the drug components administered
in the experimental schedule (Teresi et al., 2006, 2006; Gottfried
et al., 2011; Ge et al., 2012; Peng et al., 2015; van Nuffel et al., 2015;
Heudobler et al., 2018b; Chowdhury et al., 2018; Heudobler et al.,
2019b; Renner et al., 2019; Bahrambeigi et al., 2020; Batyrova
et al., 2020; Fu et al., 2020). Summarizing the present clinical
results and preclinical findings on the activity profile of single
scheduled drugs, both datasets are hypothesis generating and
suggest an impact of biomodulation on efficacy of the consecutive
nivolumab therapy in third to fifth line. That means,
biomodulation targeting dysregulated tumor-associated
homeostatic pathways, not only induces objective response
and disease stabilization, but also provides the prerequisites in
tumor tissue for improving clinical activity of checkpoint
inhibitor therapy as indicated by a similar OS compared with
the standard arm.
Contextualization
Currently, two questions in context of the treatment with
checkpoint inhibitors still remain unanswered: First, what are
the best combination partners for checkpoint inhibition, not only
showing additive activity, like cytotoxic drugs (Chen et al., 2019)?
Second, how can we prevent or break the frequently observed
resistance to checkpoint inhibitors to establish successful re-
challenge of checkpoint inhibitor therapy (Giaj Levra et al.,
2020; Metro and Signorelli, 2020)?
The study results may suggest that the chosen biomodulatory
therapy preceding the frequently used nivolumab/atezolizumab
rescue treatment may enhance checkpoint inhibitors’ activity
profile in advanced therapy line. Even if retrospectively
collected data on NSCLC without driver mutations indicate
that nivolumab is working continuously worse with increasing
number of preceding chemotherapies, the OS rate for
biomodulation in the current trial compares with those of
second-line treatment in Checkmate studies (Lang et al., 2019).
The activity profiles of the single biomodulatory components,
combined in the current treatment schedule, support the
hypothesis of a priming effect on tumor tissue. ‘Educating’
tumor tissue seems to be possible, although the single
components have poor or no monoactivity.
According to the literature, peroxisome proliferator-
activated receptors (PPAR)α/γ agonists may increase tumor
suppressor expression, as shown for phosphatase and tensin
homolog (PTEN) (Teresi et al., 2006). Enhancing the
expression of none-mutated tumor suppressor genes,
decisively attenuates tumor proliferation (Teresi et al.,
2006). Upregulation of deregulated tumor suppressor genes
in T-lymphocytes may particularly enhance their motility, a
conditio sine qua non for sufficient activity of checkpoint
inhibitors (Peng et al., 2015). Further, PPARα/γ agonists
regulate tumor cell metabolism, proliferation and down-
regulate inflammation (Gottfried et al., 2011). Moreover,
T-cell activity may be modulated by regulating metabolic
processes in T-lymphocytes, such as inhibition of glycolysis
via the PPARα agonistic component (Chowdhury et al., 2018;
Renner et al., 2019). Restricting glycolysis preserves T cell
effector functions and augments checkpoint therapies (Renner
et al., 2019). Activation of the PGC-1α/PPAR pathway during
PD-1 blockade reprograms the effector T-cell metabolism,
retains T-cell proliferative capacity and prolongs T-cell
survival.
PPARα/γ agonists may even enhance PD-1 expression
(Chowdhury et al., 2018; Renner et al., 2019). Additionally,
PPARα/γ agonists modulate the impaired lipid biosynthesis,
which hinders anti-tumor efficacy of intratumoral natural
killer T-cells (iNKT) (Fu et al., 2020).
Metronomic chemotherapy may give rise to the production of
tumor-specific T-cells, besides anti-angiogenic effects (Ge et al.,
2012). Clarithromycin also exerts pleiotropic effects, acts
immunomodulatory and angiostatic, as also shown for NSCLC
(van Nuffel et al., 2015).
Thus, the drug cocktail of the biomodulatory treatment arm
may contribute to correcting aberrant homeostasis in cancer
tissue, beyond the expected main effect, namely apoptosis
induction, a procedure called anakoinosis (Heudobler et al.,
2019b).
A clinically, still underestimated phenomenon following
chemotherapy or classic targeted therapy is the regularly
observable therapy-induced host cells’ functional shift
(Shaked, 2019), or resistance constituted by non-selective
mechanisms, e.g. metabolic plasticity of tumor tissues
(Desbats et al., 2020). In contrast to classic targeted
therapies and cytotoxic therapies, novel anakoinosis-
inducing therapies may meet potential challenges arising
with treatment-associated secondary changes in tumor
tissue by establishing novel tissue homeostasis in a
therapeutically meaningful way (Heudobler et al., 2019b). A
time to second objective disease progression (PFS2) benefit in
prospective trials or the induction of ‘biological memory’
clearly indicate the sustainable biomodulatory activity
profile of drugs or drug combinations acting as pro-
anakoinotic ‘master modifiers’ of tumor tissue (Hart et al.,
2015; Jackson et al., 2019; Bahlis et al., 2020). ‘Master
modifiers’ may prime tumor tissue in a clinically relevant
way (Hart et al., 2015; Heudobler et al., 2018a; Heudobler
et al., 2019b). The major novel therapeutic aspect introduced
by anakoinosis is considering tumor disease as a non-cell
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autonomous disease also in terms of therapeutic purposes
(Heudobler et al., 2019b).
Our study results may allow to substantiate the mentioned
hypothesis, especially in context with multifold hypothesis
supporting pre-clinical data, that biomodulation facilitates
reprogramming of tumor tissue’s homeostasis, thereby priming
NSCLC without driver mutations for more efficacious checkpoint
inhibitor therapy or even breaking PD-1/PDL1 resistance.
Therefore based on the preclinical data as well as the results
of the ModuLung trial it seems very promising to explore
combinations of biomodulatory and immune checkpoint
inhibitor therapy in future clinical trials in NSCLC.
Strengths and Limitations
The approval of checkpoint inhibitors as first line therapy for
NSCLC without driver mutations led to premature termination
of the study. Consecutively, the limited number of patients in
each treatment arm did not allow to compensate differences in
patients’ characteristics, e.g. controlled brain metastases in the
experimental arm and a shorter time from initial diagnosis to
treatment start (Martin et al., 2020; Youn et al., 2020). Although,
PFS was statistically significantly different between the study
groups, the secondary endpoint, median OS, gains particular
importance, as the frequently applied consecutive checkpoint
inhibitor therapy in patients treated in the experimental arm
completely equalized presumable disadvantages of a preceding
biomodulatory therapy or imbalanced patient characteristics. In
this context, it has to be stressed that the study was not powered
to assess non-inferiority concerning the secondary endpoint OS.
Moreover unfortunately, data on PFS2 are not available.
In summary, subsequent to this ostensibly negative result for
biomodulatory therapy concerning the primary endpoint PFS,
the biomodulatory therapy induces response in advanced
NSCLC, being translated in equivalent OS, compared to the
standard arm. Moreover, the beneficial median OS based on
successful consecutive checkpoint inhibitor therapy (65%
patients received nivolumab in third- to fifth-line), gives rise
to the hypothesis that the administered biomodulatory therapy
primes tumor tissue for efficacious checkpoint inhibitor therapy,
even in very advanced treatment lines. This hypothesis should be
tested in subsequent trials assessing the efficacy and safety of the
promising combination of biomodulatory and immune
checkpoint treatments. Biomodulation in NSCLC had a well
tolerable safety profile. Tolerability of treatment schedules in
advanced treatment lines is particularly important, as
multivariate analysis in patients receiving nivolumab reveals a
significantly increased hazard of death, in case of multiple
comorbid conditions (Martin et al., 2020; Youn et al., 2020).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Universität Regensburg, Ethikkommission, 93040
Regensburg. The patients/participants provided their written
informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
AR had the idea for and AR and CS designed the study. DH, CS,
JRF, PS, TW, TS, TS, JW, JH, FL, MV, SK, WH, and AR treated
the patients and collected the epidemiological and clinical data.
DH, TP, SH, KB, GB, and AR analyzed the data. DH, GB, and AR
drafted the manuscript. All authors critically revised the final
manuscript and are accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any
part of the work are appropriately investigated and resolved.
FUNDING
The authors declare that this study received funding from
Anticancer Fund and medac. The funders had no role in study
design, data collection and decision to publish.
ACKNOWLEDGMENTS
We thank the patients and their families and caregivers for
participating in this trial as well as all investigators and site
personnel.
REFERENCES
André, N., Carré, M., and Pasquier, E. (2014). Metronomics: towards personalized
chemotherapy? Nat. Rev. Clin. Oncol. 11, 413–431. doi:10.1038/nrclinonc.
2014.89
Bahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba,
M., et al. (2020). Daratumumab plus lenalidomide and dexamethasone in
relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a
randomized, open-label, phase 3 study. Leukemia 33, 27–49. doi:10.1038/
s41375-020-0711-6
Bahrambeigi, S., Molaparast, M., Sohrabi, F., Seifi, L., Faraji, A., Fani, S., et al.
(2020). Targeting PPAR ligands as possible approaches for metabolic
reprogramming of T cells in cancer immunotherapy. Immunol. Lett. 220,
32–37. doi:10.1016/j.imlet.2020.01.006
Batyrova, B., Luwaert, F., Maravelia, P., Miyabayashi, Y., Vashist, N., Stark, J. M.,
et al. (2020). PD-1 expression affects cytokine production by ILC2 and is
influenced by peroxisome proliferator-activated receptor-γ. Immun. Inflamm.
Dis. 8, 8–23. doi:10.1002/iid3.279
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., et al.
(2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N. Engl. J. Med. 373, 1627–1639. doi:10.1056/NEJMoa1507643
Chen, Y., Zhou, Y., Tang, L., Peng, X., Jiang, H., Wang, G., et al. (2019). Immune-
checkpoint inhibitors as the first line treatment of advanced non-small cell lung
cancer: a meta-analysis of randomized controlled trials. J. Cancer 10,
6261–6268. doi:10.7150/jca.34677
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 5995988
Heudobler et al. ModuLung Trial in r/r NSCLC
Chowdhury, P. S., Chamoto, K., Kumar, A., and Honjo, T. (2018). PPAR-induced
fatty acid oxidation in T cells increases the number of tumor-reactive CD8+
T cells and facilitates anti-PD-1 therapy. Cancer Immunol. Res. 6, 1375–1387.
doi:10.1158/2326-6066.CIR-18-0095
Ciaramella, V., Sasso, F. C., Di Liello, R., Della Corte, C. M., Barra, G., Viscardi, G.,
et al. (2019). Activity and molecular targets of pioglitazone via blockade of
proliferation, invasiveness and bioenergetics in human NSCLC. J. Exp. Clin.
Cancer Res. 38, 178. doi:10.1186/s13046-019-1176-1
Desbats, M. A., Giacomini, I., Prayer-Galetti, T., and Montopoli, M. (2020).
Metabolic plasticity in chemotherapy resistance. Front. Oncol. 10, 281.
doi:10.3389/fonc.2020.00281
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R.,
et al. (2009). New response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1). Eur. J. Cancer 45, 228–247. doi:10.1016/j.ejca.2008.
10.026
Fu, S., He, K., Tian, C., Sun, H., Zhu, C., Bai, S., et al. (2020). Impaired lipid
biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells. Nat.
Commun. 11, 438. doi:10.1038/s41467-020-14332-x
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., Angelis, F.
de., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-
small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092. doi:10.1056/
NEJMoa1801005
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., et al. (2012).
Metronomic cyclophosphamide treatment in metastasized breast cancer
patients: immunological effects and clinical outcome. Cancer Immunol.
Immunother. 61, 353–362. doi:10.1007/s00262-011-1106-3
Giaginis, C., Politi, E., Alexandrou, P., Sfiniadakis, J., Kouraklis, G., and Theocharis,
S. (2012). Expression of peroxisome proliferator activated receptor-gamma
(PPAR-γ) in human non-small cell lung carcinoma: correlation with
clinicopathological parameters, proliferation and apoptosis related molecules
and patients’ survival. Pathol. Oncol. Res. 18, 875–883. doi:10.1007/s12253-012-
9517-9
Giaj Levra, M., Cotté, F.-E., Corre, R., Calvet, C., Gaudin, A.-F., Penrod, J. R., et al.
(2020). Immunotherapy rechallenge after nivolumab treatment in advanced
non-small cell lung cancer in the real-world setting: a national data base
analysis. Lung Cancer 140, 99–106. doi:10.1016/j.lungcan.2019.12.017
Gottfried, E., Rogenhofer, S., Waibel, H., Kunz-Schughart, L. A., Reichle, A.,
Wehrstein, M., et al. (2011). Pioglitazone modulates tumor cell metabolism and
proliferation in multicellular tumor spheroids. Cancer Chemother. Pharmacol.
67, 117–126. doi:10.1007/s00280-010-1294-0
Hart, C., Vogelhuber, M., Wolff, D., Klobuch, S., Ghibelli, L., Foell, J., et al. (2015).
Anakoinosis: communicative reprogramming of tumor systems - for rescuing
from chemorefractory neoplasia. Cancer Microenviron. 8, 75–92. doi:10.1007/
s12307-015-0170-1
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., et al.
(2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,
advanced non-small-cell lung cancer (KEYNOTE-010): a randomised
controlled trial. The Lancet 387, 1540–1550. doi:10.1016/S0140-6736(15)
01281-7
Heudobler, D., Elger, T., Mayer, S., Hart, C., Vogelhuber, M., Grube, M., et al.
(2019a). Biomodulatory therapy approach with lenalidomide in combination
with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy
with treosulfan in patients with relapsed/refractory multiple myeloma >
second-line. J. Clin. Oncol. 37, 8037. doi:10.1200/JCO.2019.37.15_suppl.8037
Heudobler, D., Lüke, F., Vogelhuber, M., Klobuch, S., Pukrop, T., Herr, W., et al.
(2019b). Anakoinosis: correcting aberrant homeostasis of cancer tissue-going
beyond apoptosis induction. Front. Oncol. 9, 1408. doi:10.3389/fonc.2019.
01408
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas,
S., et al. (2018a). Clinical efficacy of a novel therapeutic principle, anakoinosis.
Front. Pharmacol. 9, 1357. doi:10.3389/fphar.2018.01357
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Pukrop, T., Herr, W.,
et al. (2018b). Peroxisome proliferator-activated receptors (PPAR)γ agonists as
master modulators of tumor tissue. Int. J. Mol. Sci. 19, 33. doi:10.3390/
ijms19113540
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., et al. (2017).
Nivolumab versus docetaxel in previously treated patients with advanced non-
small-cell lung cancer: two-year outcomes from two randomized, open-label,
phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35,
3924–3933. doi:10.1200/JCO.2017.74.3062
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., et al.
(2019). Lenalidomide maintenance versus observation for patients with newly
diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label,
randomised, phase 3 trial. Lancet Oncol. 20, 57–73. doi:10.1016/S1470-
2045(18)30687-9
Kanoh, S., and Rubin, B. K. (2010). Mechanisms of action and clinical application
of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23,
590–615. doi:10.1128/CMR.00078-09
Khandekar, M. J., Banks, A. S., Laznik-Bogoslavski, D., White, J. P., Choi, J. H.,
Kazak, L., et al. (2018). Noncanonical agonist PPARγ ligands modulate the
response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.
Proc. Natl. Acad. Sci. U. S. A. 115, 561–566. doi:10.1073/pnas.1717776115
Lang, D., Huemer, F., Rinnerthaler, G., Horner, A., Wass, R., Brehm, E., et al.
(2019). Therapy line and associated predictors of response to PD-1/PD-L1-
inhibitor monotherapy in advanced non-small-cell lung cancer: a retrospective
Bi-centric cohort study. Target. Oncol. 14, 707–717. doi:10.1007/s11523-019-
00679-9
Martin, C., Lupinacci, L., Perazzo, F., Bas, C., Carranza, O., Puparelli, C., et al.
(2020). Efficacy and safety of nivolumab in previously treated patients with
non-small-cell lung cancer: real world experience in Argentina. Clin. Lung
Cancer 12, 121. doi:10.1016/j.cllc.2020.02.014
Metro, G., and Signorelli, D. (2020). Immune checkpoints inhibitors rechallenge in
non-small-cell lung cancer: different scenarios with different solutions?. Lung
Cancer Manag. 8, LMT18. doi:10.2217/lmt-2019-0012
Mikasa, K., Sawaki, M., Kita, E., Hamada, K., Teramoto, S., Sakamoto, M., et al.
(1997). Significant survival benefit to patients with advanced non-small-cell
lung cancer from treatment with clarithromycin. Chemotherapy 43, 288–296.
doi:10.1159/000239580
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., et al. (2015).
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and
immunotherapy. Nature 527, 249–253. doi:10.1038/nature15520
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., et al.
(2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann. of Oncol. 29,
iv192–iv237. doi:10.1093/annonc/mdy275
Reichle, A. (2010). From molecular to modular tumor therapy: Tumors are
reconstructable communicatively evolving systems. Cyclooxygenase 2 and
peroxisome proliferator-activated receptor gamma expression. New York:
Dodrecht HeidelbergSpringer.
Renner, K., Bruss, C., Schnell, A., Koehl, G., Becker, H. M., Fante, M., et al. (2019).
Restricting glycolysis preserves T cell effector functions and augments
checkpoint therapy. Cell Rep. 29, 135–150. doi:10.1016/j.celrep.2019.08.068
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., Pawel, J. von.,
et al. (2017). Atezolizumab versus docetaxel in patients with previously treated
non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre
randomised controlled trial. The Lancet 389, 255–265. doi:10.1016/S0140-
6736(16)32517-X
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S.
J., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune
checkpoint inhibitor, for patients with advanced, refractory squamous non-
small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet
Oncol. 16, 257–265. doi:10.1016/S1470-2045(15)70054-9
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., and Smith, M.
A. (2005). Design issues of randomized phase II trials and a proposal for phase
II screening trials. J. Clin. Oncol. 23, 7199–7206. doi:10.1200/JCO.2005.01.149
Sakamoto, M., Mikasa, K., Majima, T., Hamada, K., Konishi, M., Maeda, K., et al.
(2001). Anti-cachectic effect of clarithromycin for patients with unresectable
non-small cell lung cancer. Chemotherapy 47, 444–451. doi:10.1159/000048556
Shaked, Y. (2019). The pro-tumorigenic host response to cancer therapies. Nat.
Rev. Cancer 19, 667–685. doi:10.1038/s41568-019-0209-6
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami,
N., et al. (2018). Atezolizumab for first-line treatment of metastatic
nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301. doi:10.1056/
NEJMoa1716948
Teresi, R. E., Shaiu, C.-W., Chen, C.-S., Chatterjee, V. K., Waite, K. A., and Eng, C.
(2006). Increased PTEN expression due to transcriptional activation of
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 5995989
Heudobler et al. ModuLung Trial in r/r NSCLC
PPARgamma by Lovastatin and Rosiglitazone. Int. J. Cancer 118, 2390–2398.
doi:10.1002/ijc.21799
Thomas, S., Schelker, R., Klobuch, S., Zaiss, S., Troppmann, M., Rehli, M., et al.
(2015). Biomodulatory therapy induces complete molecular remission in
chemorefractory acute myeloid leukemia. Haematologica 100, e4–6. doi:10.
3324/haematol.2014.115055
Ugocsai, P., Wolff, D., Menhart, K., Hellwig, D., Holler, E., Herr, W., et al. (2016).
Biomodulatory metronomic therapy induces PET-negative remission in
chemo- and brentuximab-refractory Hodgkin lymphoma. Br. J. Haematol.
172, 290–293. doi:10.1111/bjh.13480
van Nuffel, A. M., Sukhatme, V., Pantziarka, P., Meheus, L., Sukhatme, V. P., and
Bouche, G. (2015). Repurposing drugs in Oncology (ReDO)-clarithromycin as an
anti-cancer agent. Ecancermedicalscience 9, 513. doi:10.3332/ecancer.2015.513
Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M., Huebner, J.,
et al. (2015). Biomodulatory treatment of patients with castration-resistant
prostate cancer: a phase II study of imatinib with pioglitazone, etoricoxib,
dexamethasone and low-dose treosulfan. Cancer Microenviron. 8, 33–41.
doi:10.1007/s12307-014-0161-7
Walter, I., Schulz, U., Vogelhuber, M., Wiedmann, K., Endlicher, E., Klebl, F., et al.
(2017). Communicative reprogramming non-curative hepatocellular carcinoma
with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma
agonist: a phase II trial. Med. Oncol. 34, 192. doi:10.1007/s12032-017-1040-0
Youn, B., Trikalinos, N. A., Mor, V., Wilson, I. B., and Dahabreh, I. J. (2020). Real-
world use and survival outcomes of immune checkpoint inhibitors in older
adults with non-small cell lung cancer. Cancer 126, 978–985. doi:10.1002/cncr.
32624
Conflict of Interest: Author SH is employed by ClinAssess, a Contract Research
Organisation. KB and GB are employed by Anticancer Fund, a non-profit
organisation. KB and GB analyzed data, GB also drafted the manuscript
together with DH and AR.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Heudobler, Schulz, Fischer, Staib, Wehler, Südhoff, Schichtl,
Wilke, Hahn, Lüke, Vogelhuber, Klobuch, Pukrop, Herr, Held, Beckers, Bouche and
Reichle. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 59959810
Heudobler et al. ModuLung Trial in r/r NSCLC
